Patients on osimertinib with EGFR mutation exon 20, non-T790M. The position-20 trial.
- Conditions
- on-small cell lung carcinomaNiet-kleincellig longkanker
- Registration Number
- NL-OMON26966
- Lead Sponsor
- niversity Medical Center Groningen (UMCG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 15
Inclusion Criteria
1.Provision of informed consent prior to any study specific procedures
2.Patients must be ≥ 18 years of age.
Exclusion Criteria
1.Presence of a T790M mutation or other tumour driven mutations, translocations or amplifications (e.g. common EGFR mutations, KRAS, BRAF V600E, ALK, ROS1)
2.Patient is unwilling and unable to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method